Argenx has been granted a patent for a method of treating malignancy, specifically myeloid malignancies such as acute myeloid leukemia (AML), using a combination of an antibody that binds to CD70 and the BCL-2 inhibitor venetoclax. The patent also mentions the use of the antibody ARGX-110 (cusatuzumab) and the potential for synergistic treatment of AML. The combination may also include other anti-cancer agents. GlobalData’s report on Argenx gives a 360-degree view of the company including its patenting strategy. Buy the report here.

Smarter leaders trust GlobalData

Report-cover

Data Insights Argenx SE - Company Profile

Buy the Report

Data Insights

The gold standard of business intelligence.

Find out more

According to GlobalData’s company profile on Argenx, Personalized cancer vaccines was a key innovation area identified from patents. Argenx's grant share as of September 2023 was 32%. Grant share is based on the ratio of number of grants to total number of patents.

Patent granted for combination treatment of myeloid malignancy

Source: United States Patent and Trademark Office (USPTO). Credit: Argenx SE

A recently granted patent (Publication Number: US11712468B2) describes a method for treating malignancy in human subjects. The method involves administering a combination of an antibody or antigen binding fragment that specifically binds to CD70 and venetoclax or a pharmaceutically acceptable salt thereof. The antibody used in the combination has specific amino acid sequences for the heavy chain variable domain (VH) and the light chain variable domain (VL). The doses of the antibody and venetoclax are selected to provide synergistic treatment.

The patent also includes additional features and variations of the method. These include administering azacitidine or decitabine to the subject, monitoring the blast count of the subject, inducing a partial or complete response to the malignancy, inducing transfusion independence of red blood cells or platelets, increasing survival of the subject, inducing a minimal residual disease status that is negative, subjecting the subject to a bone marrow transplantation, and administering one or more additional anti-cancer agents suitable for the treatment of malignancies.

The patent further specifies various anti-cancer agents that can be used as additional treatments, such as selectin inhibitors, FLT3 inhibitors, cyclin-dependent kinase inhibitors, aminopeptidase inhibitors, JAK/STAT inhibitors, cytarabine, fludarabine, anthracycline compounds, IDH1 or IDH2 inhibitors, Smoothened inhibitors, BET bromodomain inhibitors, CD123 targeting agents, CD33 targeting agents, HDAC inhibitors, LSC targeting agents, AML bone marrow niche targeting agents, NEDD8-activating enzyme inhibitors, G-CSF, and topoisomerase inhibitors.

The method described in the patent is applicable to various myeloid malignancies, including newly-diagnosed or relapsed/refractory AML or MDS. It is particularly relevant for newly-diagnosed AML patients who are ineligible for standard intensive chemotherapy, aged 75 years or older, or have comorbidities that preclude the use of standard invasive chemotherapy.

The antibody mentioned in the patent is cusatuzumab, which specifically binds to CD70. The patent provides a comprehensive approach to treating malignancy, combining specific antibodies with venetoclax and potentially other anti-cancer agents, to achieve improved treatment outcomes in myeloid malignancies.

To know more about GlobalData’s detailed insights on Argenx, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies